Global Cholera Vaccine Oral Route Market Size By Type (Shanchol, Dukoral), By Application (Hospital, Research & Academic Laboratories), By Region, And Segment Forecasts, 2023 to 2032

The Global Cholera Vaccine Oral Route Market was valued at USD 95 million in 2023 and is projected to reach USD 178.3 million by 2031, growing at a CAGR of 8.1% during the forecast period from 2023 to 2031. This growth is driven by increased global health awareness, recurrent cholera outbreaks in endemic regions, and the rising demand for non-invasive immunization methods. The oral cholera vaccine (OCV), due to its ease of administration and efficacy in mass immunization programs, continues to gain traction in both developing and developed healthcare systems. Government-backed immunization drives, support from international health organizations such as WHO and GAVI, and growing vaccine stockpiles are catalyzing the market’s upward momentum.

Drivers:

1. Increasing Cholera Outbreaks in Endemic Regions:

Regions across Africa, South Asia, and Latin America have witnessed periodic cholera outbreaks, pushing the need for rapid-response, scalable vaccination solutions. Oral cholera vaccines have emerged as an effective preventive measure, driving global demand.

2. Supportive Government and NGO Initiatives:

Global efforts such as the Global Task Force on Cholera Control (GTFCC) and initiatives by GAVI are funding and supplying oral vaccines to high-risk populations. National immunization schedules in several cholera-prone countries have now integrated OCVs.

3. Growing Preference for Oral Delivery Routes:

Oral vaccines reduce the logistical challenges associated with injectable forms, making them ideal for remote or underserved areas. The non-invasive nature improves patient compliance, especially in pediatric and geriatric populations.

Restraints:

1. Limited Awareness in Low-Incidence Countries:

In regions with lower disease prevalence, public and institutional awareness about the importance of cholera vaccination remains limited, restricting market penetration.

2. Cold Chain and Storage Challenges:

OCVs require specific cold chain logistics for transportation and storage. Inadequate infrastructure in rural areas can hamper vaccine potency and coverage.

Opportunity:

1. Expansion into Emerging Markets:

Growing healthcare infrastructure and increased governmental health spending in countries like India, Bangladesh, Nigeria, and Ethiopia present robust opportunities for OCV deployment.

2. Development of Thermostable Vaccine Formulations:

Advancements in vaccine technology focusing on heat-stable oral cholera vaccines could significantly ease distribution barriers and enhance market adoption in remote areas.

3. Inclusion in Travel Vaccination Protocols:

As travel-related health regulations tighten post-pandemic, there’s a growing demand for cholera vaccines among travelers to endemic regions, especially aid workers and military personnel.

Market by System Type Insights:

Based on system type, Killed Whole-Cell Vaccines (e.g., Dukoral, Shanchol) held the largest share in 2023 due to proven efficacy and established use in national and global immunization programs. These vaccines are WHO pre-qualified and widely recommended for use in both preventive and outbreak response settings.

The Live Attenuated Oral Cholera Vaccines segment is expected to witness the fastest growth due to ongoing clinical trials, improved mucosal immunity, and potential for single-dose administration.

Market by End-Use Insights:

The Public Health Programs segment accounted for the majority share in 2023. Mass vaccination campaigns conducted by WHO, UNICEF, and various governments rely heavily on OCVs for epidemic prevention and control.

Traveler and Military Use is emerging as a significant growth contributor. Heightened concern over infectious disease control among deployed personnel and international travelers is expanding demand from private healthcare providers.

Market by Regional Insights:

Asia-Pacific dominated the global cholera vaccine oral route market in 2023, led by countries like Bangladesh, India, and Vietnam, which are both cholera-endemic and major manufacturing hubs for OCVs.

Africa is projected to exhibit the fastest CAGR due to recurring cholera outbreaks, increasing vaccine access programs, and rising international support.

Latin America also represents a high-potential market with improving healthcare infrastructure and disease surveillance systems in countries like Haiti and the Dominican Republic.

Competitive Scenario:

Key players in the market include Valneva SE, Bharat Biotech, EuBiologics Co., Ltd., PaxVax (Emergent BioSolutions), and Sanofi. These companies focus on WHO prequalification, cross-border supply agreements, and public-private partnerships to strengthen their global footprint.

Recent Developments:

2023: Bharat Biotech announced scale-up of its oral cholera vaccine production facility to meet growing international demand.

2024: EuBiologics received additional WHO support for its Euvichol-Plus vaccine, expanding its distribution across 15 African nations.

2025: Valneva collaborated with an international NGO to pilot a thermostable version of its Dukoral vaccine for high-temperature regions.

Scope of Work – Global Cholera Vaccine Oral Route Market

Report Metric Details

Market Size (2023) USD 95 million

Projected Market Size (2031) USD 178.3 million

CAGR (2023-2031) 8.1%

Market Segments System Type (Killed Whole-Cell, Live Attenuated), End-Use (Public Health Programs, Traveler & Military Use), Region

Growth Drivers Rising cholera outbreaks, global vaccination drives, ease of oral administration

Opportunities Expansion in emerging economies, thermostable vaccine development, traveler-specific demand

Key Market Developments:

July 2023: Bharat Biotech expanded OCV distribution in Africa with UNICEF partnership.

February 2024: WHO approved EuBiologics’ new multi-dose packaging format to reduce vaccine wastage.

March 2025: Emergent BioSolutions began clinical trials for a next-gen oral cholera vaccine targeting single-dose immunization.

FAQs

1) What is the current market size of the Global Cholera Vaccine Oral Route Market?

The market was valued at USD 95 million in 2023.

2) What is the major growth driver of the Global Cholera Vaccine Oral Route Market?

The primary growth driver is the increasing incidence of cholera outbreaks and global initiatives promoting oral immunization.

3) Which is the largest region during the forecast period in the Global Cholera Vaccine Oral Route Market?

Asia-Pacific is expected to remain the largest region due to high demand, manufacturing base, and disease prevalence.

4) Which segment accounted for the largest market share in the Global Cholera Vaccine Oral Route Market?

The Killed Whole-Cell Vaccines segment held the largest share in 2023.

5) Who are the key market players in the Global Cholera Vaccine Oral Route Market?

Leading players include Valneva SE, Bharat Biotech, EuBiologics Co., Ltd., Emergent BioSolutions (PaxVax), and Sanofi.

Let me know if you'd like a visual version or a DOCX export of this summary.